Literature DB >> 2961430

Isotretinoin therapy for acne: a population-based study.

D J Hogan1, L M Strand, P R Lane.   

Abstract

The use of isotretinoin over a 2-year period was retrospectively studied in Saskatchewan. The database of the Saskatchewan Prescription Drug Plan was used to obtain the names of physicians who prescribed isotretinoin as well as the names of patients for whom it was prescribed. Of the 861 such patients 161 had been instructed to use the drug for at least 4 months by 42 physicians. Questionnaires were returned by 86 of the 161 patients and 22 of the 42 physicians. The responses confirmed that isotretinoin therapy is highly effective for acne. However, at least half of the patients for whom the agent was prescribed apparently did not complete a full 4- to 5-month course of treatment, and of the 34 women (average age 28 years) who responded to the questionnaire 12 (35%) did not use a method of contraception, which is a matter of concern in view of isotretinoin's teratogenic effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2961430      PMCID: PMC1267508     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  12 in total

1.  Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid.

Authors:  G L Peck; T G Olsen; F W Yoder; J S Strauss; D T Downing; M Pandya; D Butkus; J Arnaud-Battandier
Journal:  N Engl J Med       Date:  1979-02-15       Impact factor: 91.245

2.  Dose-response relationship in isotretinoin therapy for conglobate acne.

Authors:  H L van der Meeren; J G van der Schroeff; T Stijnen; J A van Duren; H A van der Dries; P C van Voorst Vader
Journal:  Dermatologica       Date:  1983

3.  Use of 13-cis-retinoic acid in cystic acne.

Authors:  N Kanigsberg; J P DesGroseilliers
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

4.  Acne, hormones, and treatment.

Authors:  W J Cunliffe
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-02

5.  The local treatment of hypertrophic scars and keloids with topical retinoic acid.

Authors:  A M Janssen de Limpens
Journal:  Br J Dermatol       Date:  1980-09       Impact factor: 9.302

6.  Accutane Roche: risk of teratogenic effects.

Authors:  D P Zarowny
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

7.  Isotretinoin therapy for acne: results of a multicenter dose-response study.

Authors:  J S Strauss; R P Rapini; A R Shalita; E Konecky; P E Pochi; H Comite; J H Exner
Journal:  J Am Acad Dermatol       Date:  1984-03       Impact factor: 11.527

Review 8.  Isotretinoin treatment of acne and related disorders: an update.

Authors:  A R Shalita; W J Cunningham; J J Leyden; P E Pochi; J S Strauss
Journal:  J Am Acad Dermatol       Date:  1983-10       Impact factor: 11.527

Review 9.  Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

10.  A dose-response study of I3-cis-retinoic acid in acne vulgaris.

Authors:  D H Jones; K King; A J Miller; W J Cunliffe
Journal:  Br J Dermatol       Date:  1983-03       Impact factor: 9.302

View more
  4 in total

1.  Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern?

Authors:  Laurent Azoulay; Driss Oraichi; Anick Bérard
Journal:  Eur J Clin Pharmacol       Date:  2006-06-22       Impact factor: 2.953

2.  Making the use of isotretinoin safer.

Authors:  P R Lane; D J Hogan; A A Moreland
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

3.  The broader message of accutane.

Authors:  S R Shulman
Journal:  Am J Public Health       Date:  1989-11       Impact factor: 9.308

4.  The use of first- and second-line outpatient antibiotics under the Saskatchewan Drug Plan.

Authors:  J S McCombs; M B Nichol
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.